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Abstract: The loss of muscle mass and force characterizes muscle atrophy in several different condi-
tions, which share the expression of atrogenes and the activation of their transcriptional regulators.
However, attempts to antagonize muscle atrophy development in different experimental contexts by
targeting contributors to the atrogene pathway showed partial effects in most cases. Other master reg-
ulators might independently contribute to muscle atrophy, as suggested by our recent evidence about
the co-requirement of the muscle-specific chaperone protein melusin to inhibit unloading muscle
atrophy development. Furthermore, melusin and other muscle mass regulators, such as nNOS, be-
long to costameres, the macromolecular complexes that connect sarcolemma to myofibrils and to the
extracellular matrix, in correspondence with specific sarcomeric sites. Costameres sense a mechanical
load and transduce it both as lateral force and biochemical signals. Recent evidence further broadens
this classic view, by revealing the crucial participation of costameres in a sarcolemmal “signaling
hub” integrating mechanical and humoral stimuli, where mechanical signals are coupled with insulin
and/or insulin-like growth factor stimulation to regulate muscle mass. Therefore, this review aims
to enucleate available evidence concerning the early involvement of costamere components and
additional putative master regulators in the development of major types of muscle atrophy.
Keywords: costamere; muscle atrophy; nNOS; melusin; atrogene; dystrophin; muscle disuse;
cachexia; sarcopenia; aging
1. Introduction
Skeletal muscle atrophy represents a pathological outcome rather widespread and
consequent to several conditionns, among which are aging, bedding, muscle inactivity
(with or without loss of innervation), systemic diseases like heart failure, cancer, respiratory
insufficiency, and obesity, not to mention genetic diseases affecting skeletal myofibers.
Although muscle atrophy is characterized by the loss of muscle mass and force, it develops
in each of the above listed conditions with specific signatures [1], whose features cannot be
separated from a comprehensive mechanistic view.
Loading is one major stimulus for muscle work and growth, and reduced muscle
load, such as it occurs during prolonged bed-rest or immobilization, is a powerful driver
for atrophy development, especially in anti-gravitational muscles such as limb muscles
(soleus and vastus lateralis) [2]. Muscle mass loss is fast (about 18% in a month in a young
human, the same amount in a week in an old one) [3], mostly due to myofiber atrophy,
which involves all the fiber type populations, and is accompanied by a slow-to-fast fiber
type transition, as recently reviewed by Vikne et al. [4].
Motoneuron activity represents the other major regulator of muscle mass. Loss of
stimulation from either primary or pyramidal motoneuron quickly induces severe muscle
atrophy, which results from both loss of myofiber nuclei, secondary to increased apoptosis,
and size, and predominantly affects fast myofibers in a context where a slow-to-fast
fiber type transition occurs. Indeed, muscle response to the loss of neuronal innervation
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apparently depends on its fiber type composition, since each fiber type shows marked
difference in proteome remodeling [5].
Age-related muscle wasting (sarcopenia) leads not only to a decline in performance
and fitness of elderly people, but also to an increased risk of falls and progressive loss
of functional independence in daily activities [6,7]. Sarcopenia implies a gradual loss of
muscle strength, which starts in humans after the age of 60, often preceding the decrease
in myofiber number and size, and preferentially involving the fast fiber population [8].
The European Working Group on Sarcopenia in Older People defines sarcopenia by the
presence of low appendicular lean mass/height2 and altered muscle strength, relative
to sex-specific threshold values, and presarcopenia by the presence of decreased muscle
mass without impact on muscle force development and contraction [9]. The key difference
between disuse atrophy and sarcopenia is the presence of a decrease in size and number of
muscle fibers in the latter, whereas the former involves a decrease in fiber size only [10].
Cachexia is a multifactorial syndrome characterized by systemic inflammation, skeletal
muscle atrophy, adipose tissue wasting and metabolic abnormalities, leading to multiorgan
dysfunction. Different pathologies such as cancer, heart failure, and respiratory insuffi-
ciency may trigger this complex manifestation that is often responsible for reducing quality
of life and worsening disease outcomes [11]. Cachexia-related muscle atrophy cannot be
reversed by increasing nutrition, suggesting that important metabolic alterations are oc-
curring in the patients. Systemic inflammation, and specifically the prolonged presence of
cytokines in the circulation, has been recognized to play a causal role in this context [12–14].
Cancer cachexia and systemic diseases often lead to asthenia, where the loss of muscle
force and muscle weakness is independent from muscle mass loss. Asthenia has been
recently recognized as a relevant clinical condition, which is influenced by patient’s subjec-
tivity and difficult to diagnose [13]. Pathogenesis of asthenia at the myofiber level remains
obscure, although a reduction in muscle strength, which is not explained by a loss in muscle
mass, has been already observed during aging [15].
The pioneering studies from Bodine’s and Goldberg’s laboratories [16,17] identified
key genes, whose upregulation is shared in every of these conditions and leads to muscle
atrophy development (the so-called atrogenes). Although atrogenes are involved in muscle
protein catabolism, they represent a minor shared component of the broad transcriptome
change accompanying skeletal muscle atrophy development in each of the described condi-
tions [18]. Several additional players do contribute, and still unanswered major questions
concern whether they simply enhance atrogene upregulation or play independent and
specific key roles in their regulation. Another currently unsolved aspect is the identification
of atrophy initiators, namely the sensors, which activate/deactivate signaling pathways
leading to gene expression and atrophy development. The identification of sensors implies
taking into account muscle fiber structure, organelles and their anatomical relationships.
Among these, the costamere represents a major muscle multiprotein complex, which co-
ordinates myofibril contraction with sarcolemma and the extracellular matrix. Therefore,
the aim of this review is to present current evidence about the involvement of master
regulators and sensor candidates in the different conditions leading to muscle atrophy,
focusing on the contribution of key components of costamere structure and function.
2. Master Regulators of Muscle Atrophy
Definition of a master regulator implies its requirement, yet absolute or comple-
mentary, to initiate a biological/pathological process. Experimental models reproducing
different conditions leading to muscle atrophy have been developed and used to identify
master regulators of atrophy by means of either pharmacological or genetic tools. Detailed
reviews about the involvement of regulators of muscle transcription, protein synthesis,
and anabolic signaling pathways, protein catabolism and autophagy have recently ap-
peared [19–22]. Therefore, we would largely refer to these contributions and limit our
presentation to knowledge concerning evidence of the major or partial involvement of
these regulators with costamere components in different atrophy conditions.
Cells 2021, 10, 61 3 of 37
2.1. Transcriptional Regulators of Atrogenes
Atrogenes, i.e. genes codifying for E3 ubiquitin ligases upregulated during muscle
atrophy, are targets of several transcription factors, which act directly and independently,
although co-operative regulation has been also detected [16].
2.1.1. FoxOs
FoxOs (FoxO1, FoxO3, FoxO4) are involved in most types of muscle atrophy, since
the inhibition or genetic deletion of multiple FoxOs completely prevented its development
induced by fasting, glucocorticoid treatment and diabetes [19]. Conversely, deletion of all
FoxO family members only attenuated muscle atrophy induced by limb immobilization
and reduced, but not abolished, the expression of major atrogenes, such as MuRF1 and
MAFbx/Atrogin-1 [23]. A comparable partial effect occurred for denervation-induced
atrophy in mice with multiple FoxO KO [24]. Furthermore, FoxO apparently does not
play a role in sarcopenia development [25], whereas MuRF1 is involved, since its deletion
resulted in the maintenance of muscle mass with age [26]. Activation of FoxO3 results
from the deregulation of several signaling systems, among which are: (i) the derangement
of the Insulin Receptor (IR) cascade [19], (ii) the untethering of the neuronal isoform of
Nitric Oxide Synthase (nNOS) from sarcolemma [27–30], (iii) the excessive activation of the
anabolic response [19], possibly secondary to the lack of AMPK activation [20,31], (iv) the
loss of FoxO3 inhibitory posttranslational modifications by means of HDAC1 [32,33], and
(v) the inhibition of Akt activity by Smad2/3 signaling [34].
2.1.2. NF-κB
The family of NF-κB transcription factors consists of five members, all expressed in
skeletal muscle, RelA/p65, c-Rel, RelB, NF-κB1 (p50), and NF-κB2 (p52), forming homo-
and heterodimers. In the absence of specific stimuli, these dimers are bound to IκBs
(inhibitors of NF-κB) and kept transcriptionally inactive. The activation of the NF-κB
“canonical pathway” induces the formation of the IKK (IκB kinase) protein complex con-
taining the IKKα and IKKβ kinases and the regulatory subunit IKKγ. The activated IKK
complex phosphorylates IκB inducing its detachment from NF-κB and its degradation. As
a result, NF-κB dimers can enter the nucleus and regulate the transcription of a number
of genes mainly coding for immunoreceptors, acute phase proteins and cytokines. The
non-canonical activation of the NF-κB pathway is mediated by a specific group of stim-
uli, including ligands of a subset of tumor necrosis factor receptor (TNFR) superfamily
members, such as LTβR, BAFFR, CD40, and RANK. The engagement of these receptors
activates the NF-κB inducing kinase (NIK) that phosphorylates and activates IKKα. In
turn, IKKα phosphorylates p100 stimulating its cleavage and the generation of p52 that
together with RelB enters the nucleus to regulate gene transcription [35].
NF-κB activation increases dramatically in muscles during unloading, denervation,
cachexia and sarcopenia and the inhibition of the NF-κB pathway has been shown to
protect myofibers from atrophy in different animal models [36–43].
Both the canonical and the alternative NF-κB pathways play a role in atrophy induced
by unloading [38,43–45] and the inhibition of IKKα or IKKβ activity, through the over-
expression of dominant negative enzymes, robustly inhibits atrophy induced by 7 d of
unloading in rats [45,46]. Nevertheless, in vivo treatments with an IKKβ inhibitor failed to
inhibit expression of MuRF1 and MAFbx/Atrogin-1 after 3 d of unloading [47].
The involvement of the canonical NF-κB pathway in muscle mass regulation has
been also demonstrated using mouse genetic models. Indeed, transgenic mice express-
ing constitutively active IKKβ selectively in muscles, appear normal at birth, but rapidly
develop chronic atrophy characterized by severe muscle wasting [40]. This phenotype
is rescued by the concomitant expression of the IκB supersuppressor, a mutant form of
IκB resistant to degradation, able to inhibit NF-κB activation even in presence of IKKβ
activation [40]. It has been demonstrated that, in response to sciatic nerve resection, NF-κB
activity is increased by nine-fold after 14 d, when muscle mass has already decreased by
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60%. However, the fact that transgenic expression of the IκB supersuppressor can partially
rescue muscle mass and myofiber cross-sectional area indicates a contribution of NF-κB
activity in denervation-induced atrophy [40]. In fact, in skeletal muscles of IKKβ condi-
tional null mice denervation-induced atrophy is strongly reduced and the characteristic
shift of fibers toward a fast phenotype is impaired [41]. On the other hand, in a mouse
model of tumor-induced cachexia, muscle NF-κB activity was upregulated by six-fold after
12 d from cancer cell injection, i.e., simultaneously with myofiber atrophy appearance.
The expression of the IκB supersuppressor showed a relevant effect in inhibiting muscle
wasting and prolonging mice survival, in the absence of alterations in tumor growth [40].
The activation of the NF-κB pathway in skeletal muscle atrophy is mainly due to the
binding of cytokines on muscle surface receptors [42]. The ability of IL-1, TNF-α, and
TNF-related weak inducer of apoptosis (TWEAK) to promote skeletal muscle atrophy has
been proved in vitro and in vivo [48,49]. These cytokines, either released at distant sites, in
the case of tumor-induced cachexia [50], or locally, from skeletal muscle and neighboring
tissues, in denervation- and disuse-induced atrophy [51,52], activate the NF-κB pathway,
fostering NF-κB activity and cytokine production and generating a vicious circle. NF-κB
activation in skeletal muscle has also been found directly responsible for inducing the
expression of the ubiquitin ligase MuRF-1 [41] and for negatively regulating MyoD gene
expression [39].
2.1.3. Smad3
Smad transcription factors are activated by myostatin (a member of the TGF-β super-
family) and are potent inducers of MAFbx promoter activity [16,34].
Increased myostatin availability usually follows inflammatory conditions and extra-
cellular matrix remodeling, such as those occurring in cachexia, especially secondary to
systemic inflammatory diseases, and during aging [53]. Myostatin negatively regulates
Akt activation, enhancing atrogene expression. However, myostatin contribution appears
dispensable in the development of muscle unloading atrophy [54]. On the other hand,
myostatin is a negative regulator of satellite cell proliferation and commitment to differ-
entiation. Increased myostatin signaling has been hypothesized to play a major role in
sarcopenia development [34], although no apparent increase in myostatin levels affects
sarcopenic humans [25]. Myostatin plays a role also in cancer cachexia, where it impairs
muscle mass regulation via p53 and p21 upregulation [55].
2.1.4. ATF4
ATF4 is a transcription factor that binds to the cAMP response element and acts
as a master transcription factor for adaptation to various stress, such as endoplasmic
reticulum (ER) stress, amino acid starvation, mitochondrial stress or oxidative stress. ATF4
protein synthesis increases in response to eIF-2-alpha phosphorylation consequent to PERK
activation, and regulates gene expression of the transcription factor CHOP [56].
ATF4 is upregulated already after 3 d of muscle immobilization and increased ATF4
expression is sufficient to induce atrophy of fast-type 2 fibers, by up-regulating the tran-
scription of the cell-cycle inhibitor p21, and MuRF1 and MAFbx atrogenes [57]. Although
the involvement of p21 up-regulation in several muscle atrophy types still awaits inves-
tigations to explore possible additional functions [16], a lower number of muscle nuclei
(both satellite cell and true myonuclei) and lower BrdU incorporation characterize rat
soleus muscle after denervation, implying reduced mitotic activity, in addition to my-
onuclei loss [58]. Muscle-specific ATF4-KO mice are partially and transiently resistant
to immobilization-induced muscle atrophy, but, strikingly, they did not exhibit muscle
sparing following denervation [57]. This latter feature appears surprising, since ER-stress
response activation is a relevant component of muscle atrophy development after denerva-
tion and in cancer cachexia [21,59], in addition to other muscle disorders [60]. Strikingly,
the inhibition of ER stress with the chemical chaperone 4-PBA not only led to accelerated
muscle loss in lung cancer-bearing mice, but also to significant muscle atrophy in naïve
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mice [21]. Indeed, the ER-stress response plays a relevant role in the regulation of the
muscle mass, being involved in its maintenance in cancer cachexia and during muscle
maturation [21,61]. Such a complex contribution derives also from the peculiar role played
in skeletal muscle by some of the effectors of the ER-stress response, such as the Glucose-
regulated protein Grp94/gp96 chaperone, the Hsp90 ER-paralog. Grp94/gp96 not only
has muscle-required growth factors (GF), like Insulin-like GF-I and -II, and pro-insulin,
as exclusive clients for folding [62], but also interacts with several non-client proteins,
among which nNOS (see Section 2.2.2) and the Heregulin Receptor HER2, dictating their
subcellular distribution [63].
2.1.5. p53
The transcription factor p53 is well-known for its role in the preservation of genome
stability, as oncosuppressor, and in the promotion of the apoptotic response.
Different stimuli (unloading, denervation, aging) increase expression of p53 and target
genes in skeletal muscle, suggesting an important role in atrophy development [64–71].
In hindlimb unloading, p53 expression starts to increase within 1 d of immobilization,
before muscle atrophy onset [57]. Increased p53 expression is partially responsible for
the fiber atrophy induced by immobilization, by acting independently from the other
pro-atrophic regulator ATF4 on p21 expression [57]. Indeed, p21 is highly expressed in
adult skeletal muscle fibers during a wide variety of atrophy conditions, including muscle
disuse, fasting, aging, and systemic diseases [72]. The exact mechanism by which p53
induces atrophy is still controversial. One possibility is that p53 reduces muscle mass by
increasing the loss of myonuclei by means of apoptosis. Indeed, evidence of increased p53
expression and apoptotic index have been provided for the soleus muscle after 48 h of
hindlimb suspension [73]. Similarly, p53 protein content is markedly elevated in parallel
with the upregulation of Bax, in rat gastrocnemius muscle after 14 d of denervation [67]. In
sarcopenia the exact role of p53 is debated. Some reports suggest that chronic activation of
p53 leads to premature myofiber aging associated with a significant atrophy [74,75]. This is
confirmed by some evidence demonstrating that p53 is higher in older muscle tissue and
regulates sarcopenia [64]. Another study suggests that p53, by binding directly to the myo-
genin promoter, can repress its transcription, impairing the maintenance of muscle tissue
homeostasis [71]. Another theory suggests that nNOS controls p53 inactivation by means
of S-nitrosylation. In muscle aging, the altered shuttle of nNOS to the nucleoskeleton [76]
determines a fail in p53 S-nitrosylation, which results in MuRF-1 gene expression upregu-
lation [77]. Consistently, p53-null mice are prone to cancer development but resistant to
cancer-induced muscle atrophy [74]. In line, the muscle wasting secondary to radiation
therapy can be blocked by chemical inhibition of p53 [78]. In TNFα-induced cachexia, p53,
in concert with its target gene PW1, plays a role in blocking muscle differentiation [74].
Similarly, in doxorubicin-induced muscle atrophy p53 exerts its effect via PW1 [74]. The
expression of p53 affects differently fiber types in tumor-induced cachexia. Indeed, the loss
in fast fiber size is reduced markedly in p53 null mice. Conversely, the loss of p53 induces
only a mild effect in slow fibers [74].
2.1.6. Hippo Pathway
The Hippo pathway, by means of the MST1-kinase cascade, negatively regulates the
activation of YAP/TAZ, and cell proliferation and apoptosis in organ development [22].
In the skeletal muscle, YAP positively regulates basal skeletal muscle mass and protein
synthesis.
Loss of muscle innervation activates the Hippo pathway and the inhibition of MST1
is sufficient to prevent atrophy in denervated, fast-twitch muscles [79]. Conversely, but
in parallel, denervation increases YAP protein amount and activity in myonuclei, as a
compensatory pro-trophic signal to attenuate muscle atrophy development [80]. YAP/TAZ
positively regulate satellite cell/myoblast activation, and we tentatively speculate that
dysfunctions in this pathway might play a relevant role in muscle atrophy development,
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especially in sarcopenia, where reduced recruitment of satellite cells appears to be mecha-
nistically involved in loss of muscle mass [81]. However, such a hypothesis needs to be
confirmed by further extensive investigations, especially in the light of a recent report
about the pro-atrophic role played by YAP in a genetic model of sarcopenia [82].
2.2. Oxidative and Nitrosative Stress
Oxidative stress, together with nitrosative stress, represents a major player of muscle
atrophy development. Systemic inflammation or diseases accompanied by inflammatory
responses, such as heart failure, respiratory insufficiency and cancer, obviously account
for higher levels of diffuse oxidative stress. Conversely, its increase during muscle disuse,
such as following denervation or immobilization, remains still to be fully explained, since
oxidative stress represents a relevant byproduct of muscle activity [83,84].
Increased oxidative stress in the inactive muscle derives from the imbalance between
the muscle anti-oxidant defense, reduced by the increase of protein catabolism, and the
physiological oxidant production [85]. However, the upregulation of chaperones and
enzymes involved in the anti-oxidant defense occurs before muscle atrophy development,
supporting the hypothesis that the increase in oxidant production anticipates the increase
in protein catabolism [86,87]. Available evidence concerns increased accumulation of ox-
idative modifications, such as the presence of protein covalent adducts (carbonylation,
binding of the 4-hydroxyl-nonenal moiety, tyrosine nitrosylation, advanced glycation end
products) or oxidized species (disulphide bond covalent species) by means of biochem-
ical/immunochemical assays [30,86,88–91]. Indeed, unbiased direct demonstration of
increased oxidant accumulation requires specific approaches/probes and use of intact
muscle or isolated myofibers [83,92]. The hypothesis that oxidative stress, like calcium
ions, may rise and act locally, as well as globally, in the muscle fibers to initiate signaling in
distinct subcellular compartments [84] should be also taken into account when discussing
either positive or negative findings.
2.2.1. Reactive Oxygen Species (ROS)
Putative sources of increased ROS production in skeletal muscle have been extensively
reviewed [85,93] and identified in mitochondria and NADPH-oxidases, by means of the
use of specific inhibitors. NADPH-oxidases appear the major source of cytosolic ROS
during acute exercise bouts and are involved in exercise-induced changes, such as the
translocation of the glucose transporter 4 (GLUT-4) and the activation of pro-trophic
pathways [84]. Mitochondrial ROS have been suggested to increase post-exercise only,
i.e., at rest [84]. Indeed, dysfunctional mitochondria characterize long periods of muscle
inactivity [93] and both dysregulation of mitochondria fusion and alteration in structure
and function negatively affect muscle mass in several conditions [94]. Skeletal muscle
atrophy, secondary to unloading, denervation, fasting or FoxO3 overexpression, relieves
after counteracting the downregulation of PGC-1α, the master regulator for mitochondrial
biogenesis [95,96]. Therefore, reduced mitochondrial renewal might explain the organelle
deterioration and its decrease in respiratory capacity.
Additional possible mechanisms leading to increased mitochondrial ROS production
after prolonged muscle unloading/inactivity were identified by changes in cardiolipin
amount and composition [97], or increased mitochondrial Ca2+ secondary to ryanodine
receptor 1 (RYR1) leakage [98]. On the other hand, only a few studies concerned the early in-
volvement of mitochondrial dysfunction in atrophy development by unloading/inactivity.
Mitochondria-targeted antioxidants, such as SS-31 and MitoTEMPO [99], were adminis-
tered to laboratory rats before exposure to either a 12 h bout of mechanical ventilation [88]
or a 6 h bout of hindlimb unloading [30]. In both cases, scavengers blunted the increase in
oxidatively modified proteins and hampered the signaling required for atrophy progres-
sion, in the former case by reducing atrogene expression [88], and, in the latter one, by
counteracting the loss of active nNOS from sarcolemma, an event which induces FoxO3
nuclear translocation [30]. Interestingly, SS-31 targets cardiolipin, optimizing mitochon-
Cells 2021, 10, 61 7 of 37
drial electron transport and ATP synthesis [100], but changes in cardiolipin amount and
composition after short exposure to muscle inactivity have not been investigated yet. The
requirement of mitochondrial ROS production was apparently ruled out by the recent
finding that transgenic mice expressing catalase in mitochondria are not protected from
atrophy induced by 7 d-unloading [101], at variance with other reports where exogenous
catalase expression or administration of mimetics [89,102] appeared effective in attenuating
it. As recognized by Authors themselves, such a discrepancy might be explained either by
experimental differences (recombinant mitochondrial-directed catalase is effective against
muscle atrophy of the unloaded rat [102]) or by the major involvement of superoxide anion,
the hydrogen peroxide precursor.
Although increased hydrogen peroxide production from muscle mitochondria has
been detected only 3–5 d after transection of the peroneal nerve or the sciatic nerve, respec-
tively [103,104], a recent extensive transcriptomic analysis, performed at different times
after sciatectomy, indicates a very early role for oxidative stress in denervation-induced
muscle atrophy [87]. Increased transcript accumulation for genes involved in calcium
release, oxidoreductase activity and antioxidant activity, occurs between 30 min and 12 h
after sciatectomy, compared to controls that underwent surgery without denervation.
Interestingly, cytochrome P450 appeared among the most activated signaling pathways,
suggesting endosomes as the preferential early ROS source in the denervated myofiber [87].
2.2.2. Reactive Nitrogen Species (RNS)
The contribution of NO, NOS and nitrosative stress to muscle atrophy development
is still controversial, despite of the abundant evidence concerning their involvement in
muscle atrophy [20,90,105,106]. A major point of disagreement concerns the actual avail-
ability of NO during muscle atrophy development. It has to be mentioned that adequate
measurements of NO require isolated muscle and use of spin-trap electron paramagnetic
resonance [27,107,108]. Opposite results were obtained with such a technique in the soleus
muscle after 7d-unloading [27,109]. As suggested by Sharlo et al. [109], a possible ex-
planation for this discrepancy derives from methodological aspects (use of intact frozen
muscles [109] vs minced muscle maintained at room temperature [27]). Unfortunately, this
approach does not discriminate between endothelial and myofiber NO sources.
In the skeletal myofibers, NO is synthesized by the neuronal nNOSµ isoform that local-
izes at sarcolemma by tethering to the dystrophin glycoprotein complex (DGC) (Figure 1).
At present, no controversy exists about the redistribution of the nNOSµ isoform from
sarcolemma to sarcoplasm after exposure to unloading or denervation [27,30,89,110,111],
whereas contrasting reports concern actual enzyme and NO levels [27,107–109,111,112].
The possibility that variable atrophy degree and/or duration of denervation/unloading
affected nNOS levels was explored by extensive transcriptomic and proteomic analyses
in rat soleus muscle after different unloading times (from 6 h to 7 d) [30]. Results showed
an early and severe, but transient, decrease of both nNOS mRNA and protein, which
returned at physiological levels after about 7 d-unloading, however, without the recovery
of the physiological subcellular localization at sarcolemma [27,28,30,89]. Consequently, NO
production in myofibers is expected to vary during unloading, because of changes in the
enzyme amount, in addition to the site of production [20,105,113].
The beneficial pro-trophic effects of NO are largely recognized [113] acting on pro-
trophic signaling [106]. Exogenous administration of NO-donors or L-arginine was indeed
effective in attenuating unloading-induced muscle atrophy [107,114] and the drop of satel-
lite cell proliferation [114]. However, the same effects were observed also in the dystrophic
muscle [107,115] which expresses very low levels of nNOS, arguing whether another NOS
isoform (the endothelial one?) might be involved in this response. Alternatively, L-arginine
might act upon and stabilize those nNOS molecules still tethered at sarcolemma [107].
However, such a possibility has not been investigated yet. Conversely, misplaced sarcoplas-
mic NO production has been hypothesized to lead to unwanted consequences, first of
all to FoxO3 activation, as showed by overexpressing nNOS in cultured myotubes [27].
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Since maturation of the DGC requires more than 7 d growth in differentiation media, the
overexpressed nNOS enzyme localizes meanwhile exclusively in the sarcoplasm. Compa-
rably, in the absence of dystrophin, i.e., in the dystrophic muscle, the extremely low level of
sarcoplasmic nNOSµ is nevertheless responsible for decreased muscle performance, which
ameliorated after the expression of a mini-dystrophin construct and enzyme docking at
sarcolemma [116] or of a palmitoylated nNOSµ that tethers directly at sarcolemma [117]. It
is relevant to recall that any beneficial effect consequent to the sarcoplasmic overexpression
of the less active nNOSα isoform did not involve the myofibers at all, but only reduced the
population of M2 macrophages and the degree of fibrosis [118].
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SR-ER = sarco-endoplasmic reticulum; IGF1 = insulin-like growth factor 1.
In the unloaded soleus muscle, the knocking-out of nNOS gene or the inhibition
of its activity attenuated FoxO3 activation and muscle atrophy [27]. Silencing of nNOS
mRNA before a 6-h unloading bout, abolished FoxO3 accumulation in myonuclei [30].
The same effect, concomitantly with the attenuation of muscle atrophy, occurred when
physiological muscle levels of the Grp94 chaperone, which interacts with nNOS mostly in
the sarcoplasmic reticulum (SR)/ER, were specifically maintained during unloading by
means of gene transfer or pharmacological treatment [28,29]. Blunting of FoxO3 nuclear
accumulation, and muscle atrophy attenuation, req ired physiological levels of Grp94 that
operated by targeting nNOS to sarcolemma [28,29]. I a c mparable way, Grp94 is requir d
to t rget HER2 molecules to cancer cell plasmalemma and improve viability [119].
In addition to generate regional changes in NO production, the redistribution of
nNOS to the sarcoplasm might facilitate an “uncoupled” NADPH oxidation (uncoupled
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from NO formation), decreasing NO production and generating superoxide anion [120]
(Figure 1, inset). Neuronal NOS has a particular propensity to catalyze this “uncoupled”
reaction. Furthermore, because of the very rapid reaction of superoxide with NO, the
synthesis of both species by the same enzyme, which exists as a dimer, is likely to result in
peroxynitrite formation [120], fostering nitrosative stress. The hypothetical accumulation of
“uncoupled” active nNOS molecules in the sarcoplasm would be consistent with both the
evidence of reduced NO production in unloaded muscles [107–109] and the requirement of
an active sarcoplasmic nNOS to activate FoxO [27,30]. Indeed, histochemistry for NADPH-
diaphorase [30,121], which is widely used to demonstrate the subcellular localization
of active nNOS molecules, detects only the activation of the carboxy-terminal reductase
domain, which acts upstream and provides electrons to the NO-generating oxidase domain
in the “coupled” conformation, or directly to O2 when “uncoupled” [120].
2.3. Mechanotransduction
Major determinants of muscle activity are the neuromuscular junction (NMJ) and the
ability to sense mechanical stretch through costameres, i.e., multiprotein complexes that
function as mechanotransducers, transforming mechanical load in biochemical signals,
which, in turn, trigger specific responses in terms of gene expression, protein synthesis and
organization. Skeletal muscle expresses a number of mechanotransducers with different
sensitivity and specific responses to tension. Costameres align between the sarcolemma and
underlying sarcomeric myofibrils coincidently with Z-discs and M-lines, and connecting
them to the extracellular matrix (ECM) [122–124]. Although a high number of costamere
components belongs to the cytoskeleton, relevant members, such as the DGC, integrins
and ionic pumps/channels, localize at the sarcolemma [124] (Figure 2). Components of the
DGC are essential for mechanoprotection from shear stress and reduce contraction-induced
injury [125]. Integrins collect forces spreading laterally to the long axis of the sarcomere,
from each myofibril to the neighboring one, and channel them across the sarcolemma
to the extracellular matrix, by providing up to 70% of the muscle contraction force [123].
Costamere proteome shows a fiber-type specialization, which appears to be involved
in dictating sarcomere composition during resting, loading and after pharmacological
immobilization with botulin toxin [126,127].
In addition to nNOS, which is a component of DGC, recent investigations provided
relevant and further evidence of the regulatory role of costamere components on muscle
mass [128,129]. Our laboratories demonstrated the requirement of the integrin-binding,
chaperone protein melusin to counteract muscle disuse atrophy [128], whereas another
report identified plakoglobin as the mediator of physical and functional interaction between
DGC and the Insulin receptor (IR) [129]. These and previous pieces of evidence further
amplify the concept of a costamere as more inclusive, where a sovramolecular complex
hosting different protein–protein interactions serves as a “signaling hub”, as dubbed by
Eid Mutlak et al. [129], to regulate myofiber size.
2.3.1. Dystrophin Glycoprotein Complex (DGC)
Dystrophin, sarcoglycans, dystroglycans, syntrophins are major components of the
DGC, which hosts several others relevant regulators, such as nNOS and the recently
identified interactor plakoglobin [129] (see the Section 2.3.3), and works, together with
integrins, to provide a tight connection between the sarcomere and ECM components
like laminin and the heparan sulfate perlecan [15,130–133]. At the core of the DGC is
dystrophin, a large 427-kDa protein, which interacts with actin filaments at its amino
terminus and connects to the sarcolemma by binding to β-dystroglycan and α1-syntrophin
at its carboxyl end.
Cells 2021, 10, 61 10 of 37
Cells 2021, 10, x 10 of 38 
 
complex hosting different protein–protein interactions serves as a “signaling hub”, as 
dubbed by Eid Mutlak et al. [129], to regulate myofiber size. 
 
Figure 2. The sarcolemmal costamere components and their interactors form a supramolecular 
platform specialized in mechanostransduction and signal integration (only a part of the compo-
nents is shown in the figure). ECM = extracellular matrix; ILK = integrin-linked kinase; MLP = 
muscle LIM protein; FAK = focal adhesion kinase; nNOS = neuronal nitric oxide synthase; PI3K = 
phosphoinositide 3-kinase IRS-1 = insulin receptor substrate-1; IGF1R =insulin-like growth factor 1 
receptor; SR = sarcoplasmic reticulum. 
2.3.1. Dystrophin Glycoprotein Complex (DGC) 
Dystrophin, sarcoglycans, dystroglycans, syntrophins are major components of the 
DGC, which hosts several others relevant regulators, such as nNOS and the recently iden-
tified interactor plakoglobin [129] (see the Section 2.3.3), and works, together with integ-
rins, to provide a tight connection between the sarcomere and ECM components like lam-
inin and the heparan sulfate perlecan [15,130–133]. At the core of the DGC is dystrophin, 
a large 427-kDa protein, which interacts with actin filaments at its amino terminus and 
connects to the sarcolemma by binding to β-dystroglycan and α1-syntrophin at its car-
boxyl end. 
Among the conditions leading to muscle atrophy, loss of dystrophin usually occurs 
as a late event, probably because of the extreme long life of this protein [134]. In aged 
muscle, dystrophin loss preferentially affects flexor muscles and is accompanied by in-
creased amount of other DGC and costamere components, such as β-dystroglycan, α-
sarcoglycan, sarcospan, desmin and muscle LIM protein [135]. Conversely, reduced dys-
trophin protein levels, but not transcript ones, represent an early event in cachexia devel-
opment, since they occurred before the reduction in mean fiber diameter [136]. A loss of 
dystrophin is accompanied by hyperglycosylation of β-dystroglycan and β-sarcoglycan, 
and by a loss of interactions between β-dystroglycan and α-dystroglycan, or dystrophin, 
Figure 2. The sarcolemmal costamere components and their int ractors form supramolecular platform pecialized in
mechanostransduction and signal integration (only a part of the components is shown in the figure). ECM = extracellular
matrix; ILK = integrin-linked kinase; MLP = muscle LIM protein; FAK = focal adhesion kinase; nNOS = neuronal nitric oxide
synthase; PI3K = phosphoinositide 3-kinase IRS-1 = insulin receptor substrate-1; IGF1R =insulin-like growth factor 1 receptor;
SR = sarcoplasmic reticulum.
Among the conditions leading to muscle atrophy, loss of dystrophin usually occurs as
a late event, probably because of the extreme long life of this protein [134]. In aged muscle,
dystrophin loss preferentially affects flexor muscles and is accompanied by i creased
amount of other DGC and costamere components, such as β-dystroglycan, α-sarcoglyca ,
sarcospan, desmin nd muscle LIM protein [135]. Conversely, reduced dys rophin protein
levels, but not transcript o s, repr sent an early event in cachexia development, since
they occurr d before the reduction i mean fiber diamet r [136]. A loss of dystrophin is
accompanied by hyp rglycosylation of β-dystroglycan and β-sarcoglycan, and by a loss
of int racti ns between β-dystroglyca and α , or dystrophin, w thout overt
changes in the subcellular localization of the former proteins. Dystrophin overexpression
in mice c unteracted cancer-induced muscle loss and atrogene expression, indic ting DGC
disruption as a maj r switch of cachexia develop nt [136]. Interestingly, insulin resist nce
develops during cachexia, such as in the presence f l dystrophy r other types of
muscle atrophy, enclosed that one accomp nying obesity [137]. Indeed, as will be reviewed
in Section 2.3.3, the DGC appears to be connected physically and functionally to the IR
by means of β-dystroglycan binding to plakoglobin [129]. Therefore, DGC deregulation
influences IR signaling and the way around.
Indeed, in the absence of an early loss of dystrophin, other events, such as the
unloading- and denervation-induced untethering of the nNOSµ isoform [27,105], are
suggestive of DGC derangement. The enzyme, assembled either in homodimer (µµ) or
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heterodimer (µβ) conformation, binds both α1-syntrophin and the spectrin-like repeats
16–17 of dystrophin by means of its PDZ domain [120,138]. Although nNOS is a cytosolic
protein, its docking at sarcolemma requires interaction with the ER chaperone Grp94/gp96,
which exists both in lumenal and transmembrane form [28]. In fact, reduced levels of Grp94,
as it occurs early in unloading-induced atrophy, jeopardize the targeting of newly synthe-
sized nNOS molecules at sarcolemma and result in increased enzyme concentration in the
sarcoplasm [28–30], where nNOS fosters both oxidative and nitrosative stresses and FoxO3
activation, as discussed at point 2.2.2 (Figures 1 and 3). The cytosolic chaperone Hsp90
interacts with nNOS, positively affecting its activity and favoring NO production compared
to superoxide [120]. Hsp90 and nNOS interaction is increased by muscle training [139],
whereas Hsp90 protein levels show only a late reduction after unloading [140]. Interest-
ingly, nNOS, assembled with α-syntrophin, β-dystroglycan, α1-, β-, α2-dystrobrevins, and
the carboxyterminal-form of dystrophin Dp71, can localize in the nucleus [76]. Such a
complex modulates p53 transcriptional activity in myofibers by means of S-nitrosylation,
since the lack of this post-translational modification, which occurs in p53 from old muscles,
upregulates atrogene expression [77].
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2.3.2. Integrins and Integrin-Associated Signaling
A number of experimental data points to a crucial role of integrins in this context. Inte-
grins ar large f mily of heterodimeric transmembrane proteins formed by the association
of alpha and be subunits, able to bin s to ECM proteins with their extracellular doma ,
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and to the intracellular cytoskeleton through their cytoplasmic regions. Integrins confer
more than a physical link between intracellular and extracellular supramolecular structures,
in fact they also mediate bidirectional signaling through the plasma membrane, regulating
a number of cellular events, including cell migration, adhesion, and proliferation [141].
The α7β1 integrin is highly expressed in skeletal muscle fibers and specifically localizes at
costameres and myotendinous junctions [142], where it physically connects the ECM to
the sarcomeric contractile apparatus [143]. This location is particularly suitable to sense
mechanical stretch. Indeed, tension generated by contraction induces integrin activation
and promotes integrin expression, reinforcing cell adhesion to the ECM and enhancing
integrin-dependent signaling [144]. Activated integrins, which are connected to the actin
cytoskeleton through their intracellular interactors talin and vinculin, cluster along my-
ofiber plasmamembrane and form specialized structures called focal adhesions [145]. The
transmembrane proteoglycan syndecan-4 localizes at costameres as well [146,147] and
cooperates with integrins in the assembly of focal adhesions and in cytoskeleton organi-
zation [148]. Of note, syndecan-4 expression is robustly downregulated after 72 h from
denervation [147].
Mechanical strain induces focal adhesion enlargement and stabilization and promotes
the recruitment and activation of intracellular signaling molecules. The focal adhesion
kinase (FAK) is a non-receptor tyrosine kinase that, upon binding to integrins, undergoes a
conformational change that induces its autophosphorylation. This event allows the kinase
Src to bind to FAK and to phosphorylate two additional tyrosine residues, mediating its
complete activation. FAK activation in skeletal muscle has been described in response to
mechanical strain-induced muscle loading, while unloading and denervation decrease FAK
expression and phosphorylation [149–156], in a muscle-specific-way [127]. FAK carries on
the signal by activating different pathways, such as MAPK and PI3K/Akt pathways, that
promote muscle hypertrophic programs [157].
The integrin-linked kinase (ILK) is highly expressed in skeletal muscle, in particular in
type II fibers [126], and localizes at myotendinous junctions and costameres, where it binds
the cytoplasmic domain of the β1 integrin [158]. ILK recruits actin regulatory proteins,
as PINCH, parvin, paxillin, and kindlin [159], impacting on the organization of the actin
cytoskeleton. Of note, ILK acts as a connector between the integrin mechanotrasduction
apparatus and the insulin-like growth factor I receptor (IGF-IR) signaling platform, cou-
pling mechanical strain to Akt phosphorylation [158,159]. The skeletal muscle-specific
inactivation of ILK coding gene alters integrin distribution at the myotendinous junctions,
causes a partial detachment of the sarcolemma from the basal membrane, and leads to
a progressive muscular dystrophy [158,160]. These features are further aggravated by
exercise training, which induces muscle cell necrosis and fibrotic depositions. In response
to mechanical strain, phosphorylation of IGF-IR and its downstream effector Akt is im-
paired in ILK-depleted skeletal muscles [158], suggesting a role for ILK in transducing
trophic signals in skeletal muscles. Indeed, ILK is upregulated in muscles in response to
exercise [126,161] and it has been involved in transducing hypertrophic stimuli in cardiomy-
ocytes [162–164]. Consistently, transcripts for members of both integrin- and ILK-signaling
decrease significantly after 5 d-bed rest in both young and old humans [165].
Melusin is a small chaperone protein encoded by the ITGB1BP2 gene and selectively
expressed in the striated muscle tissue, and able to interact with the cytoplasmic domain
of integrin β1. From a phylogenetic point of view, melusin has a highly conserved struc-
ture, consisting of two cysteine and histidine-rich domains (CHORDS), a domain shared
by CHORD proteins and by the co-chaperone protein Sgt1 (CS domain) [166] and a C-
terminal Ca2+-binding domain [167]. CHORD I-II domains are zinc-binding domains able
to mediate the association of melusin to the ATPase domain of HSP90, in its ADP-bound
state [168–171]. The CS domains, structurally similar to α-crystallin and p23 chaperone
proteins [172], have been also involved in Hsp90 binding [170,173]. The interaction be-
tween melusin and Hsp90 is further favored by the binding of Ca2+ to the C-terminal
domain, enriched in aspartic and glutamic acid residues [171]. Melusin has been found in
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complex with FAK and with IQGAP-1, a scaffold protein for the mitogen activated protein
kinases c-Raf, MEK1/2 and ERK1/2 [174,175] and with the phosphatidylinositide 3-kinase
(PI3K) that activates Akt [176]. In response to mechanical stretch, melusin triggers the
integrated activation of ERK1/2 and Akt, promoting cardiomyocyte survival and hyper-
trophy [177]. In the myocardium, melusin expression is induced by mechanical overload.
Indeed, melusin expression levels increase in response to mechanical stress, in conjunction
with the compensatory hypertrophic response of the left ventricle [168,178–180]. During
the subsequent phases of maladaptive remodeling, characterized by chamber dilation,
fibrotic tissue deposition and consequent loss of contractile function, melusin expression
progressively decreases [178]. Melusin-null mice fail to induce a compensatory hyper-
trophic response to mechanical overload and rapidly develop a dilated cardiomyopathy,
confirming the importance of melusin in regulating cardiomyocyte hypertrophy [181]. The
overexpression of melusin protects the myocardium from different challenging conditions,
from pressure overload to myocardial infarction and reperfusion injury [178,182–185],
promoting the establishment of a physiological hypertrophic response.
The role of melusin in skeletal muscles has been far less investigated. Melusin starts to
be expressed in embryo limbs at 15 d gestation with a peak in newborn muscles. Melusin
is highly expressed during secondary myogenesis, when additional myoblasts fuse along
the surface of primary myotubes to form secondary myotubes. Melusin expression is main-
tained in adult skeletal muscles, where it localizes at costameres, and is further induced
during muscle regeneration after trauma [167]. Melusin has been found upregulated in
muscle from patients affected by limb-girdle muscular dystrophy type 2A (LGMD2A),
where it regulates the replacement of the integrin β1A isoform with the β1D isoform,
affecting costamere assembly and myotube fusion [186]. We recently identified melusin as
a crucial player in muscle atrophy induced by disuse [128]. Muscle unloading induces a
drastic and very early drop in melusin expression, well before the onset of muscle atrophy.
Indeed, melusin protein level decreases to 50% in rat soleus already after 6 h from tail
suspension. A decline in melusin expression has been also noted in the vastus lateralis of
patients after eight days of bed rest, suggesting a conserved role in human muscles [128].
Maintenance of physiological levels of melusin expression during unloading by means
of cDNA transfection or AAV-9-based gene therapy attenuated muscle atrophy and im-
proved muscle contraction in rats. Of note, forced melusin expression did not affect nNOS
activity and FoxO3 nuclear translocation, while clearly dampened Atrogin-1 and MuRF1
expression [128]. The molecular mechanism by which melusin inhibits unloading-induced
muscle atrophy does not involve the activation of Akt and ERK pathways, since the co-
expression of dominant-negative versions of these kinases did not blunt melusin efficacy
in counteracting atrophy [128].
The muscle LIM protein (MLP) is a muscle-specific protein containing two LIM do-
mains involved in protein-protein interactions, able to localize in different cytoplasmic
locations, where it binds to different interactors [124,187]. MLP plays crucial structural
functions in cardiac muscle, regulating the assembly of supramolecular complexes along
the sarcomere and at the Z-disk, as demonstrated by the presence of cytoskeletal dis-
array in cardiomyocytes and by the development of dilated cardiomyopathy and heart
failure in MLP-null mice [188]. Mutations in MLP coding gene are associated with hu-
man cardiomyopathy [189] and cause hypertrophic cardiomyopathy and heart failure in
mice [190]. Mild abnormalities have been disclosed in skeletal muscle of MLP-null [191]
and mutant mice [190], suggesting a role for MLP in maintaining muscle mass and skele-
tal muscle passive stiffness. Of note, MLP expression levels have been found increased
in muscles from mouse models and human patients affected by different types of my-
opathies [192–194]. Recently, MLP has been also involved in promoting autophagosome
formation by interacting with LC3, protecting myocytes from apoptosis [195]. MLP local-
izes at costameres, where it interacts with zyxin [196], β1-spectrin [197] and ILK [198]. Of
note, MLP may enter the nucleus and regulate gene transcription by acting as co-activator
of transcription factors involved in muscle differentiation such as MyoD, myogenin and
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MRF4. Interestingly, all these transcription factors appear upregulated in the denervated
muscle [199] and MRF4 silencing was demonstrated to abolish denervation-induced muscle
atrophy [199]. Transcriptomic data indicate a drop of MLP expression already at 24 h from
unloading [68], suggesting a role for MLP in connecting integrin mechanotrasduction to
gene expression regulation.
2.3.3. IR/IGF-R
Although IR and IGF-IR are not considered as a canonical component of costameres,
the findings demonstrating a physical interaction with several proteins belonging to DGC
and integrin complex through plakoglobin [129] or ILK/PINCH [158,159,200], prompt to
include these receptors as relevant players. The contribution of IR and its downstream
signaling through PI3K-Akt-FoxO to muscle mass regulation is widely acknowledged
and of paramount relevance [19]. Indeed, the impairment of IGF-1/insulin signaling
induces per se muscle atrophy that can be rescued by triggering the PI3K/Akt/FoxO3
pathway [201,202]. Therefore, this review will focus here only on evidence concerning the
interaction of the IR signaling pathway with costamere components. Evidence concerning
the early disruption of IR signaling in different contexts of muscle atrophy development
will be provided in the next section, together with that one concerning IGF-IR, since both
receptors participate in IR signaling pathway [203].
The conductor orchestrating IR and DGC function is represented by plakoglobin
(γ-catenin), a desmosomal protein, which in skeletal muscle displays a spot-like distribu-
tion in sarcoplasm and sarcolemma, where it colocalizes with dystrophin [204]. Plakoglobin
binds to IR and serves as a key component in its interaction with and activation of PI3K
and downstream Akt-FoxO signaling. Plakoglobin interaction with PI3K, but not that
one with IR, is disrupted by the ubiquitin-ligase Trim 32, which operates on thin filament
proteins, Z-band components, and the cytoskeletal costamere-interacting protein desmin.
Differently from these targets, Trim32 interaction with plakoglobin does not result in the
protein degradation, but in the silencing of PI3K-Akt signaling and in muscle atrophy [204].
A recent investigation showed that plakoglobin participates in a native multimeric as-
sembly, which includes, in addition to IR, DGC components (dystrophin, sarcoglycans,
dystroglycans and syntrophins), vinculin, caveolin-1, laminin, and desmin. Precisely,
plakoglobulin colocalizes with β-dystroglycan and vinculin, in addition to dystrophin and
IR [129]. Proximity ligation assays and domain mapping showed that IR interacts with
plakoglobin N-terminus, and β-dystroglycan binds to plakoglobin sites adjacent to this
region. Dystrophin binds to plakoglobin central armadillo repeat domain. Such a physical
and functional interaction between IR and DGC might mechanistically drive the increased
nNOS activation, secondary to Ser1412 phosphorylation, which occurs in skeletal muscle
after 10 min of systemic insulin administration [205]. Conversely, reduced plakoglobin
protein levels not only affect IR signaling, but also decrease assembly of DCG components
and vinculin and promote desmin depolymerization [129].
2.3.4. Na+/K+ ATPase and Ion Channels
Costamere includes other relevant plasmalemmal components, such as the sodium/
potassium pump and the sodium channel [123]. Their inclusion is mediated through
ankyrin B and D binding and subsequent anchoring either to spectrin filaments or to the
spectrin-like repeats in the dystrophin central region [123,206].
The relevance to consider the sodium/potassium pump is due to its signaling function,
in addition to the electrogenic one, in muscle mass regulation (i.e., in cardiac hypertrophy)
and in ROS-generation, following its inhibition by ouabain [207]. Partial inhibition of
Na+/K+-ATPase stimulates c-Src- and Ras-dependent signaling, which leads to mitochon-
drial ATP-sensitive potassium (KATP) channel-related ROS generation. Like ouabain,
increases in both exogenous and endogenous ROS can cause conformational changes in
Na+/K+-ATPase and enzyme partial inhibition. Such a signaling cascade involves the α1
subunit of Na+/K+-ATPase, whereas the α2 subunit, which represents about the 80% of the
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α subunits in the skeletal muscle, appears to be more involved in electrogenic regulation
of muscle contraction, fatigue resistance and exercise performance [208]. Nevertheless,
both subunits are upregulated by resistance training in human muscle [209]. Investigations
on Na+/K+-ATPase deregulation in muscle atrophy development are scanty and circum-
scribed to muscle unloading, where the inhibition of α2 subunits occurs after 6–12 h of
unloading, secondary to cholesterol loss from the sarcolemma [210]. A recent study also
demonstrated a relevant role of AMPK in the maintenance of α2 subunit activity during a
12-h unloading bout [211].
The voltage-gated sodium channel determines the upstroke as well as the refractory
period of the action potential. The density of available sodium channels in the sarcolemma
differs between slow and fast fiber populations and greatly influences the firing pattern,
which in turn contributes to their phenotypic feature. Both unloading and denervation
affect Na+ channel expression, but in different manner. The protein levels of the adult
skeletal muscle α-subunit isoform of Na+-channel encoded by the SCN4A gene, transiently
increase after one week unloading only in slow-twitch muscles, concomitantly with the
change towards a fast-twitch phenotype [212]. Conversely, the increase in total Na+-channel
mRNA synthesis induced within a week by denervation is accompanied by the appearance
of the juvenile/cardiac, tetrodotoxin-resistant Na+-channel isoform and of hemichannels
(HCs) formed by connexins 39, 43, and 45. Connexin 43 and 45 hemichannels lead to
activation of the p65 subunit of NF-κB and up-regulation of pro-inflammatory cytokines
(TNF-α and IL-1β) [213].
Stretch-activated channels (SACs) are non-specific ion channels that respond to me-
chanical stress by altering their opening probability and have functional relationships with
the DGC and integrins [214–216]. SAC opening has been connected to the activation of the
Akt/mTOR pro-trophic pathway in skeletal muscle [217]. It has been recently suggested
that SACs might undergo functional inactivation during unloading, possibly contributing
to atrophy establishment [218]. Among SACs, the stretch-activated and Ca2+ permeable
TRPC1 channel is expressed in skeletal muscle and interacts with α-1-syntrophin PDZ
domain and caveolin-3 [219–223]. This channel has been found to be responsible for anoma-
lous extracellular Ca2+ entry in dystrophic muscle fibers [220,222,223]. Downregulation
of TRPC1 in adult mouse muscles induces atrophy per se, pointing to a relevant role of
this channel in muscle mass regulation [224]. TRPC1 expression is downregulated during
muscle unloading and raises again during reloading [224,225] and if TRPC1 expression is
suppressed in the reloading phase, muscle regrowth is impaired [224].
3. Involvement of Costamere Components in Different Muscle Atrophy Types
The emerging picture from the present literature review indicates a wide variety of po-
tential master regulators of muscle atrophy, whose enrollment during atrophy onset follows
the activation of more than a signal transduction pathway and leads to decreased protein
synthesis and/or increased protein degradation. Given the differences existing among
muscle atrophy phenotypes, a major aim of this review is to enucleate early and relevant
players among costamere components and, possibly, hypothetical initiators, presenting
available evidence from each research field.
3.1. Unloading/Bed Rest/Immobilization
Although all of these three conditions imply reduced muscle load, only immobiliza-
tion leads to effective loss of muscle activity. During unloading or bed rest, leg gravitational
muscles are free to contract, but suffer the absence of body load, which they usually hold in
standing position. Indeed, muscle atrophy resulting from each of these conditions shows
subtle, yet interesting differences, in muscle contractility, transcriptome and proteome [226].
A number of studies investigated more deeply the effects of short exposure to unload-
ing/inactivity, demonstrating that several events anticipate the morphological evidence of
muscle atrophy (Figure 3 and Table 1).
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Myosin and actin pre-mRNA transcription decreases already after 24 h-unloading [2],
whereas FoxO3, p53, and MAFbx/Atrogin-1 transcript levels quickly increase after expo-
sure to both unloading and immobilization (24 h and 48 h, respectively) [31,68,128,227]. In
contrast, time of MuRF-1 mRNA accumulation appears controversial (after 4–7 d of unload-
ing [68,128], 24-h unloading [31] or 48 h-immobilization [227]). FoxO3 upregulation occurs
concomitantly with the decrease of Akt activity (24 h-unloading) [128] and the increase
in protein ubiquitination and deacetylation (48 h-immobilization) [227]. Loss of active
Akt and deacetylation are recognized activators of FoxO3 nuclear translocation [32], the
former resulting from blunted IR signaling and the latter from class I HDAC non-histone
activity [33].
Another relevant early player involved in FoxO3 activation by unloading is the loss
of AMPK activity [19,20,31]. The decrease in AMP levels, secondary to reduced/absent
activity in otherwise continuously active gravitational muscles, such as the soleus muscle,
leads after 12–24 h of unloading to inactive AMPK accumulation, increased ceramide
concentration and p70S6K activation. These detrimental effects, which lead to increased
protein synthesis, presumably of key proteolysis regulators, partially relieved after the
administration of AICAR (an AMPK activator) [31]. However, AICAR did not blunt
MAFbx/Atrogin-1 and MuRF-1 upregulation [31], suggesting that other pathways than
phosphorylated p70S6K are involved. Indeed, protein levels of a major target of p70S6K, the
Insulin Receptor Substrate 1 (IRS-1), whose Ser-phosphorylation hampers IR signaling and
Akt activation, are also significantly decreased after 24 h-unloading [31]. IRS-1 proteostasis
appears to be under the control of the ubiquitin-ligase Cbl-b [228], which increases its
activity during unloading. Although an early involvement of increased Cbl-b activity has
still to be demonstrated, Cbl-b ablation fully counteracted unloading-induced FoxO3 and
MAFbx/Atrogin-1 accumulation, muscle mass, and force loss in mice [228].
The early qualitative and quantitative disruption of the IR-signaling pathway ap-
parently follows costamere components disruption, i.e., the decrease in melusin protein
levels [128] and the loss of nNOS sarcolemmal activity [30], both of them being detectable
6 h after unloading. Melusin loss is not apparently detrimental for the activity of several
of its targets, among which Akt, ERK1/2 and FAK, as shown by melusin replacement
together with dominant-negative form of these kinases [128]. Conversely, the redistribution
of active/uncoupled nNOS molecules appears to be required upstream FoxO3 nuclear
translocation, since decreased nNOS expression, following mRNA interference, or in vivo
pharmacological inhibition of its enzyme activity, blunted FoxO3 activation [30]. Recent
evidence demonstrated the presence of a functional/spatial relationship between DGC
and IR, which is lost during fasting (i.e., in a condition leading to muscle atrophy) [129].
The possibility exists that the same “signaling hub” is perturbed by unloading-induced
dysfunctions, such as nNOS untethering from DGC, and IRS-1 degradation and/or Ser-
phosphorylation occurring roughly simultaneously, and resulting in downstream FoxO3
nuclear translocation. Interestingly, plakoglobin transcripts appear to be upregulated
already 1 d after unloading [68], suggesting a compensatory response to early costamere-IR
deregulation. Simultaneously with the loss of sarcolemmal nNOS activity, unloading
affects the integrin component of costamere. Melusin loss occurs early and before the evi-
dence of atrophy, both in humans (8 d-bed rest) [128] and in rodents (6 h unloading) [128],
leading, through still undefined effectors, to atrogene upregulation independently from
FoxO3 activation. In fact, melusin replacement attenuated atrophy by means of full down-
regulation of MAFbx/Atrogin-1 and partial silencing of MuRF-1 and, without affecting
FoxO3 nuclear localization and upregulation, which, conversely, appeared paradoxically
increased [128]. Indeed, unloading muscle atrophy did not develop after counteracting
both melusin loss and nNOS-induced FoxO3 activation. Therefore, unloading-induced
muscle atrophy results by the early, parallel and independent involvement of two master
regulators: one is FoxO3, activated by the dysregulation at the DGC-IR signaling hub, the
other one is the loss of melusin, which primarily involves MAFbx/Atrogin-1 upregulation.
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Further investigations are necessary to complete the downstream signaling switched on by
decreased melusin levels.
Table 1. Temporal sequence of events induced by unloading/inactivity in rodent hindlimb muscles before the appearance
of myofiber atrophy.
Time Localization Event Consequences Reference






α-actinin and β- and γ- actin
subsarcolemmal cytoskeleton
reorganization [229,230]
loss of active sarcolemmal
nNOS FoxO3 nuclear translocation [30]
decreased sarcolemmal NO
production AMPK inactivity [20]
sarcoplasm increased accumulation ofactive/uncoupled nNOS increased NO/ROS production [30]
mitochondria ROS production loss of active sarcolemmalnNOS [30]
ROS production covalent S-S tropomyosinspecies [30]
sarcolemma loss of cholesterol membrane instabilityloss of Na/K pump activity [210,231]
inhibition of 2subunit of Na/K
pump membrane instability [231]
nucleus increased FoxO3 localization transcriptional activity [30]
decreased nNOS transcription decreased nNOS protein [30]
12 h sarcoplasm AMPK inactivity p70S6K activation loss ofNa/K pump activity [20,211]
ceramide accumulation sarcolemma instability [210]
increased phospo-p70S6K pSer-IRS-1 [20,31]





nucleus increased FoxO3 transcription increased protein levels andatrogene upregulation [31,68,128,227]
myosin gene down-regulation fiber type transition [2]
multiple transcriptional
changes phenotype change [68]
sarcoplasm/nucleus increased p53 protein levels MuRF-1 and p21 upregulation [57]








mitochondrial release of AIF;
caspase -3 and caspase-8
activation




evidence of muscle atrophy [30]
Upstream events leading to disruption of both melusin and nNOS await to be fully
clarified. Untethering of nNOS from sarcolemma, but not loss of melusin, depends upon
increased mitochondrial ROS production occurring after 6 h-unloading [30,128]. Inter-
estingly, ROS upregulate Cbl-b, which deregulates IR signaling [232]. The mechanism
involved in increased mitochondrial ROS production after a 6 h-unloading bout is presently
unknown. Interestingly, disturbance in lipid distribution and composition of junctional
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and non-junctional sarcolemma occurs after 6–12 h of unloading [210,231], concomitantly,
and probably consequently, to the loss of the Na+/K+ pump activity, which appears to
be regulated in the soleus muscle by both motor activity and sarcolemmal lipid stability
(Table 1). Unloading-induced disturbance of sarcolemmal lipids decreases the stiffness
of the subsarcolemmal cytoskeleton, mainly composed by non-muscle α-actinin and β-
and γ-actin [229]. Indeed, lecithin treatment before 6 h-unloading fully prevented it [230].
Since non-muscle α-actinin binds integrin-related costamere components, such as vin-
culin and MLP, and γ-actin represents a required component for costamere integrity [124],
re-organization of the subsarcolemmal cytoskeleton might be considered as putatively
responsible for early costamere and integrin-melusin signaling disruption, eventually
leading to disassembly of the DGC-IR, in addition to mitochondrial ROS production.
3.2. Denervation/Spinal Cord Injury
Although both nerve crush/transection and spinal cord damage lead to loss of muscle
functional responses and induce severe muscle atrophy, there are relevant differences
concerning time of appearance of atrophy and type of paralysis [213]. Due to the abun-
dant literature in the field, only data concerning loss of innervation, secondary to nerve
transection or compression, or inhibition of neurotransmitter release, will be the object of
this review.
As reported for immobilization/unloading, identification of early events requires
knowledge of time of appearance of muscle atrophy (Table 2). Available evidence are
still controversial: whereas one report indicates 48 h after sciatectomy as the earliest
detection time of soleus muscle atrophy, measured by muscle weight normalization to
the contralateral innervated one [233], no significant difference in myofiber cross-sectional
area was reported at the same stage by another laboratory [234]. Other reports indicated
muscle atrophy occurrence three days after denervation, by comparing muscle weight
of the denervated muscle either to the contralateral innervated one [235], whose use as
a control was recently recognized as a source of potentially flawed results [236], or to
age-matched controls [237]. The determination of the earliest evidence of myofiber size
loss is crucial to identify upstream events, which might differ from those involved after
muscle unloading/immobilization.
A recent trascriptomic analysis of denervated mouse tibialis anterior muscle detects
atrogene up-regulation only 3 d after sciatectomy [87], in agreement with previous evidence
on mouse and rat gastrocnemius muscle [237,238] and at variance with unloading, where
atrogene upregulation is detectable already after 24 h [68,128]. Day 3 after sciatectomy
also represents the earliest evidence for HDAC4 involvement in denervation atrophy
development [235,239]. Although it was suggested that HDAC4 upregulation promoted
muscle atrophy by increasing the myogenin-dependent FoxO3 activation [239], recent
evidence indicate that the non-histone deacetylase activity of the enzyme has a prominent
pro-catabolic effect on different targets, such as molecular chaperones (Hsc70), myofibrillar
proteins (myosin heavy chains), and transcription factors (PGC-1α) [240]. Indeed, the
acetylated (inhibited) FoxO3 form is strongly reduced 3 d after denervation [32]. Strikingly,
HDAC4 nuclear import to exert histone-deacetylase activity requires the activation of Akt-
mTORC1 signaling, i.e., the main inhibitor of FoxO gene family transcriptional activity [235].
Such a paradoxical context appears, however, necessary to allow HDAC4-dependent
synaptic gene expression and endplate maintenance in the denervated muscle.
Recent investigations provided a major advance in knowledge of early events in the
development of denervation-induced muscle atrophy by analyzing muscle transcriptome
at different times after denervation, from less than 0.5 h to 28 d. Major findings were
the up-regulation of genes involved in the oxidative stress and inflammatory responses
within 0.5–24 h after denervation [59,87]. Inflammation contributes to muscle atrophy
development in several contexts [241]. Its early activation after denervation might be
related to nerve injury and stump degeneration [242] and/or to the early increase in
muscle levels of oxidative stress, as suggested by the upregulation of cytochrome P450
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and monooxygenase transcripts, together with others involved in the anti-oxidant defense,
about 3 h after denervation [87,243]. Activation of NF-κB and pro-inflammatory cytokines,
secondary to de novo expression of connexins after one-week denervation, also contributes
to muscle atrophy [213].
The actual knowledge of oxidative stress source(s) in the denervated muscle remains
elusive. Transcripts of both PCG-1α and β, the regulators of mitochondrial prolifera-
tion, dramatically decrease after 24 h-denervation [237], suggesting early impairment of
mitochondrial pool renewal. Monoamine oxidase A transcript and protein content was
found to be increased between 3–24 h after denervation [87,244]. However, ROS produc-
tion from mitochondria apparently increased later than 48-h denervation [103,104,244],
possibly in concomitance with increased mitochondria misplacement at A band [245].
The possibility exists that other ROS sources do contribute to a very early increase in
oxidative stress. Deregulation of intracellular Ca2+ levels might represent a possible ini-
tiator. Interestingly, changes in Ca2+ release and uptake from the SR lead to transiently
reduced levels of stored Ca2+ as early as after 48 h-denervation, and, conversely, to their
increase after 7-d denervation [234]. Mitochondrial Ca2+ uptake appears to be reduced
after 3-d denervation [245]. We tentatively speculate that the earlier deregulation of Ca2+
cycling follows the transitory increased expression (between 0.5 and 6 h after denervation)
of genes involved in ion release and binding in the cytosol [87]. The biological signifi-
cance of this transient increase in cytosolic calcium levels remains obscure. In addition to
excitation-contraction coupling, both the sarcolemmal calcium channel/dihydropyridine
receptor and the SR calcium channel/RYR1 play a relevant regulatory role in NMJ devel-
opment and destabilization [246]. Furthermore, through Ca2+-calmodulin, Ca2+ transients
might stimulate nNOS coupled and uncoupled activity, fostering both ROS and RNS
accumulation [120]. Calcium ions also increase phospholipase A2 (PLA2) activity [247].
Phospholipase A2 de-esterifies membrane phospholipids, which can promote enzymatic
(i.e., via lipo-hydroperoxidases) and non-enzymatic peroxidation of bis-allylic unsaturated
lipids and activate NADPH-oxidases [248]. Interestingly, muscle lipo-hydroperoxides
increase between 2–4 d of denervation consequently to cytosolic PLA2 activation [59].
Protein levels of peroxiredoxin 6, which has potential PLA2 activity, also increase after
3 d-denervation [244]. Calcium depletion from SR stores might trigger an ER-stress re-
sponse in denervated myofibers [21]; increased expression of the transcription factor ATF4
was observed within 2–4 d after denervation [59]. Increase in sarcoplasmic calcium levels
also affects costamere components. By means of calpain activation, desmin is proteolyzed
after 4 d-denervation [249]. Interestingly, proteolysis followed desmin interaction with and
phosphorylation by GSK3-β and Ca2+-calmodulin kinase, and protein ubiquitination 3 d
after denervation [249].
Denervation-induced dysregulation of costamere components may represent an early
target. After 3-d denervation, the levels of syndecan-4, a cell surface heparan-sulfate pro-
teoglycan co-operating with integrins and involved in PKC signaling, are reduced [147].
Accordingly, transcript downregulation of focal adhesion components and ECM receptors
was reported after 6-h denervation [87]. Interestingly, some nPKC forms are selectively
recruited in the muscle membrane fraction as early as 24-h denervation [250]. Available
evidence concerning gene expression dysregulation of costamere components, among
which melusin [251], and nNOS redistribution to sarcoplasm [27,110,126,252] were col-
lected only after the establishment of denervation atrophy (i.e., after 7–14 d). A recent
report identified perlecan-α-dystroglycan interaction as a major site responsible for nNOS
untethering from DGC as early as 4 d after denervation [253]. Indeed, no reduction in nNOS
sarcolemmal localization and attenuated muscle atrophy were observed in denervated
gastrocnemius of perlecan KO mice [253]. Preliminary data obtained in our laboratory
reveal that the nNOS-interacting Grp94/gp96 chaperone and melusin are involved very
early after denervation, since the levels of these two proteins significantly decreased from
one day after denervation (M. Brancaccio and L. Gorza, unpublished observations). Early
denervation-induced derangement of costamere proteins has still to be fully investigated,
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but several studies focused on IR signaling, a major component of the costamere signaling
hub [129]. The occurrence of insulin resistance (decreased glucose uptake) appears as
early as 24 h after denervation, although without alteration in the IR ability to bind insulin
or transfer downstream signaling to PI3K and Akt [254], and it is followed by a marked
GLUT-4 downregulation 3 d after denervation [255].
Table 2. Temporal sequence of events induced by denervation in rodent hindlimb muscles before the appearance of
myofiber atrophy.
Time Localization Event Consequences Reference
0.5–6 h nucleus






oxidative stress; increased YAP
[59,80,87]
decreased gene transcription for:
focal adhesion and extracellular
receptors
reduced mechanotransduction [87]
3 h sarcolemma neuromuscolar junction disruption AChR clustering [256]
6 h sarcoplasm increased protein levels of Hippokinase MST1 and YAP reduced YAP signaling [22]
nucleus YAP localization increased YAP signaling [22]
24 h sarcolemma/costamere inhibition of IR signaling withoutAkt inhibition decreased glucose uptake [254]
sarcoplasm increased Monoamine oxidase A oxidative stress [87,244]




nucleus PCG- and - genes down-regulation reduced mitochondriogenesis [237]
up-regulation of pro-inflammatory
genes activation of NF- B pathway [59,87,213]
48 h SR decreased Ca2+ uptake reduced levels of stored Ca2+ [234]
reduced levels of stored Ca2+ ER stress response [21]








reduced muscle mass earliest evidence of muscleatrophy [233,235,237]
nucleus increased ATF4 expression ER stress response [59]





reduced syndecan 4 reduced integrin signalling [147]
mitochondria misplacement at A band reduced connection with triadsand Ca2+ uptake [245]




nucleus FoxO3, HDAC4 upregulation atrogene up-regulation [87,235,237–239]
GLUT-4 down-regulation reduced glucose import [255]
sarcoplasm increased peroxiredoxin 6 increased phospholipase A2activity [244]
Eventually, components of the DGC are also relevantly involved in the stabilization of
the NMJ, whose disruption is evident in most myofibers 3 h after denervation. Similarly
to unloading, denervation perturbs the membrane lipid composition by dispersing the
cholesterol-rich lipid membrane domains where post-synaptic proteins reside, among
Cells 2021, 10, 61 21 of 37
which the acetylcholine receptors, and some DGC components [256]. Interestingly, the pro-
growth transcription factor YAP accumulates in adult muscle fibers at the membrane near
the NMJ. The DGC, together with agrin, an essential regulator of NMJ stability, is involved
in YAP inhibition through Hippo signaling [22]. Denervation results in accumulation
of the Hippo-pathway kinase MST1 and increased YAP abundance as early as 6 h after
sciatectomy. Sustained increase in YAP transcription, phosphorylation at Ser112, and total
protein occurred along 14 d post-denervation, concomitantly with the protein localization
in myonuclei [22].
3.3. Cachexia
A common mechanism inducing cachexia in patients affected with cancer and different
pathological conditions is represented by circulating factors, which may originate from
different tissues and include cytokines, extracellular vesicles, hormones, and growth
factors. These systemic mediators may act directly on skeletal muscle cells or indirectly by
inducing a metabolic rewiring in other tissues that will subsequently drive skeletal muscle
wasting [11,257].
Pro-inflammatory cytokines bind to surface receptors on muscle cells and trigger
signaling pathways that cooperate to induce and activate ubiquitin ligases and autophagy
regulators, promoting protein catabolism. Indeed, TNF-α, TWEAK, and IL-1 activate
NF-κB, known to induce MuRF1 and to promote protein catabolism. Interferon-γ and IL-6
activate the STAT3 pathway that induces cytokine production and cooperates with NF-κB
in promoting atrophy [257,258]. MAP kinase signaling cascades involving ERK, p38 and
JNK have also been involved in inducing cachexia in different studies [259–261].
Myostatin family proteins have been reported to play a crucial role in cancer cachexia.
By binding the surface receptor ActRIIB, they activate Smad2/3 signaling pathway, promote
FoxO3 activity and the subsequent transcription of Atrogin-1 and MuRF1. The inhibition
of ActRIIB cascade reverts muscle loss and improves survival in different cancer mouse
models [262–264]. In line, the inhibition of the Smad2/3 signaling by overexpressing the
Smad inhibitory protein Smad7 prevents muscle cachexia in cancer bearing mice [265].
Systemic stress signals mediated by chaperone proteins are able to trigger skeletal
muscle atrophy. Stressed cells, as cancer cells or cardiomyocytes subjected to mechanical
overload, activate unconventional mechanisms of protein secretion [266]. The chaperone
proteins Hsp70 and Hsp90 are released in a soluble form or on the surface of extracellular
vesicles and, once reached skeletal muscle fibers, bind to Toll-like receptor (TLR) 4 and
trigger the p38 pathway, inducing muscle wasting [267].
On the other hand, the attenuation of trophic pathways as IGF-1 and insulin mediated
signals on skeletal muscle fibers contributes to muscle cachexia too. IGF-1 and insulin acti-
vate, through PI3K, the serine threonine kinase Akt, a potent inhibitor of FoxO3 [268–270].
In cachectic rodents and patients, the expression of IGF-1 in muscles and in the circulation
decreases [271–273] In one study, IGF-1 administration has been shown to reduce weight
loss and improve survival in cancer-bearing rodents [274]. Of note, cachectic cancer patients
suffer of insulin resistance and administration of insulin [275] or insulin sensitizers [276]
may reduce muscle wasting [137,277]. It has been recently demonstrated that plakoglobin
connects DGC to IR and the disruption of this supramolecular complex impairs insulin
signaling and induces muscle atrophy [129], suggesting that insulin resistance may depend
on the alterations of costamere integrity. The forced reduction of plakoglobin expression
levels in muscle results in impaired PI3K/Akt signaling and muscle atrophy [204]. Inter-
estingly, it has been shown that the plasma membrane of cachectic muscle fibers show an
irregular morphology, due to the decrease in dystrophin expression by post-translational
mechanisms, the concomitant upregulation of utrophin, and the aberrant glycosylation
of β-dystroglycan and β-sarcoglycan [136]. Destabilization of the DGC may therefore
represent a new mechanism through which cachectic factors induces muscle loss.
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3.4. Sarcopenia
Sarcopenia development has been attributed to multiple mechanisms, among which
a major role has been hypothesized for the increase in both oxidative and nitrosative
stresses [91,278], the loss of innervation [7,279], and the decreased regenerative potential of
muscle stem cells [81,280].
ROS accumulation by dysfunctional mitochondria, consequent to impaired removal
by autophagy [281], elicits senescence and the onset of age-related diseases. Increased
protein carbonyl adducts characterize old skeletal muscle mitochondria, independently
of sarcopenia [282]. The possibility that partial muscle denervation, which accompanies
muscle aging, would increase ROS production in the remaining innervated fibers, and,
therefore, promote sarcopenia, was confirmed by the evidence of generalized myofiber
atrophy and increased mitochondrial ROS levels [104].
To the aged muscle dysfunctions contributes the nitrosative stress, secondary to
increased NO production and nNOS/eNOS protein levels, which accumulate in the sar-
coplasm [91,283–285]. However, decreased nNOS enzyme level and activity, and targeted
S-nitrosylation in sarcopenic muscle have been reported too [286,287]. We cannot therefore
exclude that such a controversial body of evidence reflects species- and muscle-specific
differences. The failure in S-nitrosylation fosters both atrogene expression and myofibrillol-
ysis [77,287]. The reduced S-nitrosylation of p53, secondary to a defective shuttle of nNOS
to the nucleoskeleton, results in MuRF-1 gene upregulation [77], which is among the few
atrogenes involved in sarcopenia [7,26]. In fact, FoxO3 activation appears modest in aging
muscles [25], whereas p53 protein level is higher compared to the adult one [64]. Lack
of calpain S-nitrosylation leads to increased proteolysis of myofibrillar proteins (myosin
and troponins) and the intermediate filament scaffold (desmin), and to a minor proteolytic
modification of α-actinin, which could disrupt interactions between thin filaments and the
Z-disk [287].
The accumulation of oxidatively modified proteins and protein aggregates in the pres-
ence of myofibrillolysis points to a dysregulation of the intracellular proteolytic systems.
Proteasomal activity is declining in the aged muscle, whereas the autophagy-lysosomal sys-
tem shows a muscle-specific derangement, being severely impaired in fast-twitch muscles,
whereas only mildly reduced in slow-twitch ones [90].
Increased remodeling of muscle connective tissue and availability of myostatin have
been also considered as possible initiators of sarcopenia [53]. However, the variable
results concerning serum and muscle myostatin levels and loss of muscle mass in humans
apparently rule out a major role for this signaling pathway [25], despite the evidence
of sarcopenia decrease following myostatin inhibition in animal investigations [34]. In
fact, myostatin KO or administration of anti-myostatin antibodies attenuated muscle
fiber atrophy, enhanced muscle functional capacity, and reduced apoptosis in skeletal
muscles of aging mice [288]. On the other hand, myostatin negatively regulates satellite
cell proliferation and commitment to differentiation, reducing the recruitment of satellite
cells [81]. In addition, increased levels of p53 may decrease satellite cell commitment by
binding directly to the myogenin promoter and repressing transcription [71].
Costamere composition is affected variably by aging. Changes at this level or at
costamere anchoring to myofibrils may lead to impaired force transfer and cause the loss in
muscle strength occurring in the aged muscle, especially in the presence of a light reduction
in muscle mass [15]. The major change concerns the loss of dystrophin, which, in the very
old rat, occurs in a muscle-specific manner, before appearance of myofiber atrophy, and
independently from gene expression [289]. In old rat plantaris, discontinuous membrane
expression of dystrophin and α-syntrophin are accompanied by reduced sarcolemmal
nNOS localization [285]. In contrast, in murine old soleus, the sarcolemmal distribution
of the active enzyme remains largely detectable, showing increased accumulation at dis-
crete foci (L.Gorza, unpublished observation), despite the reduction in total nNOS protein
levels (Samengo et al. 2012; L. Gorza unpublished observations). Reduced dystrophin
levels decrease lateral force transmission, leading to sarcomere and NMJ instability and
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subsequent contraction-induced injury [289,290], despite the presence of increased expres-
sion of other DGC and costamere components [285,289]. Although exposure of hindlimb
muscles of aged rats to unloading did not reduce further dystrophin protein levels, the
compensatory increase of DGC and costamere components does not prevent the muscle
membrane damage and regeneration following reloading [135].
Desmin participates in the DGC compensatory response of old muscles, by increasing
protein levels in a muscle-specific way [289,291,292]. Strikingly, desmin phosphorylation
levels are increased in the aging muscles [291], suggesting ongoing depolymerization of
desmin filaments [249]. In addition to link adjacent myofibrils to each other at the periphery
of sarcomere Z-discs and M-bands, desmin filaments anchor them to the sarcolemma,
via plectin and costameres, as well as to the mitochondria and the nucleus, playing a
major role in the maintenance of sarcomere alignment [124]. A two-dimensional finite-
element model, developed to investigate the mechanical contribution of desmin in a fixed-
end contraction, predicted a higher maximum stress production when desmin filaments
concentrate in the subsarcolemma, compared to the fiber center [293]. Both increased
folding of sarcolemma, and loss and disorganization of subsarcolemmal myofibrils occur
in aged myofibers, favoring desmin accumulation in intermyofibrillar and subsarcolemmal
spaces, as suggested by the coarser pattern of labelling with anti-desmin antibodies [294].
The possibility exists that the increased desmin accumulation would contribute to the age-
dependent increase of muscle stiffness, which is relevant to the preservation of eccentric
force generation in the elderly [295].
Despite the presence of signs of DGC derangement, IR signaling does not appear to be
disrupted during aging [25], such as it occurs in the absence of dystrophin expression [129].
Such a feature deserves further investigations, taking into account the body of evidence
concerning the muscle-specific loss of dystrophin and/or the fiber-type specific responses
to aging [1,135,285,289].
4. Conclusions
Although the investigation on early events leading to muscle atrophy is still at its
beginning, the possibility that more than one master regulator is required and involved
in the atrophic process is supported by increasing experimental evidence. The costamere
appears as the least investigated muscle compartment during muscle atrophy development,
compared to myofibril proteins or mitochondria. Nevertheless, recent investigations indi-
cate this site as the most crucial one, because of the regulatory coupling among IR/IGFR
and DGC/integrin, and the most responsive one, for the early deregulation of its compo-
nents involved in nitrosative/oxidative stress and signaling regulation, such as nNOS and
melusin in unloading-induced muscle atrophy.
Further studies are therefore required to determine the contribution of costamere
deregulation to the development of other muscle atrophy types, although a few available
evidences are already suggestive of an early involvement of some of its components.
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Abbreviations
4-PBA 4-phenyl butyric acid
AAV-9 Adeno-associated virus serotype 9
Ac Acetylation
ActRIIB Activin receptor type IIB
AICAR 5-amino-imidazole-4-carboxamide ribonucleotide (AMPK activator)
Akt Protein kinase B
AMP Adenosine monophosphate
AMPK AMP-activated protein kinase
ATF4 Activating transcription factor 4
ATP Adenosine triphosphate
BAFFR Tumor necrosis factor receptor superfamily member 13C
cAMP Cyclic adenosine monophosphate
Cbl-b Casitas B-lineage lymphoma-b ubiquitin ligase
CD40 Cluster of differentiation 40
CHORDS Cysteine and Histidine-Rich Domains
c-Raf RAF proto-oncogene serine/threonine-protein kinase
c-Rel Proto-oncogene c-Rel
CS CHORD and Sgt1 domain
DGC Dystrophin glycoprotein complex
ECM Extracellular matrix
ERK1/2 Extracellular signal-regulated kinase 1/2
FAK Focal adhesion kinase
FOXO1/3/4 Forkhead box O1/3/4
GLUT-4 Glucose transporter 4
Grp94/gp96 Glucose-regulated protein 94/glycoprotein 96
GSK-3β Glycogen synthase kinase-3β
HDAC1/4 Histone deacetylase 1/4
HER2 Receptor tyrosine-protein kinase erbB-2
Hsp90 Heat shock protein 90
IGF1R Insulin-like growth factor 1 receptor
IGF-I and –II Insulin-like growth factor I and II
IKKα/β Inhibitor of nuclear factor kappa-B kinase subunit α/β
IL-1 Interleukin 1
ILK Integrin-linked kinase
IQGAP-1 IQ Motif Containing GTPase Activating Protein 1
IR Insulin receptor
IRS-1 Insulin receptor substrate-1
ITGB1BP2 Integrin beta-1-binding protein 2
IκB Inhibitor of nuclear factor kappa B
JNK c-jun N-terminal kinase
LGMD2A Limb-girdle muscular dystrophy type 2A
LTβR Lymphotoxin-β receptor
MAFbx Muscle atrophy F-box ubiquitin ligase
MAPK Mitogen-activated protein kinase
MEK1/2 Dual specificity mitogen-activated protein kinase kinase 1/2
MLP Muscle LIM protein
MRF4 Myogenic regulatory factor 4
MST1 Macrophage stimulating 1
mTORC1 Mammalian/mechanistic target of rapamycin
MuRF-1 Muscle RING finger—1 ubiquitin ligase
MyoD Gene coding for Myoblast determination protein 1
NADPH Nicotinamide adenine dinucleotide phosphate
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells
NF-κB1 Nuclear factor NF-kappa-B p105 subunit
NF-κB2 Nuclear factor NF-kappa-B p100 subunit
NIK NF-κB inducing kinase
NMJ Neuromuscular junction
nNOS Neuronal nitric oxide synthase
NO Nitric oxide
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p38 MAPK p38 mitogen-activated protein kinase
p70S6K Ribosomal protein S6 kinase p70
PCG-1α and β Peroxisome proliferator-activated receptor-gamma coactivator 1α and β
PDZ domain PSD-95/Dlg/ZO-1 domain
PI3K Phosphoinositide 3-kinase
PINCH Particularly interesting new Cys-His protein 1
PKC Protein kinase C
PLA2 Phospholipase A2
PW1 Gene coding for Paternally-expressed gene 3 protein
RANK Tumor necrosis factor receptor superfamily member 11A
RelA/p65 Transcription factor p65
RelB Transcription factor RelB
ROS Reactive oxygen species
RYR1 Ryanodine receptor 1
SAC Stretch-activated ion channel
SCN4A Gene coding for Sodium channel protein type 4 subunit alpha
Smad Small mother against decapentaplegic
SR Sarcoplasmic reticulum
TAZ Transcriptional coactivator with PDZ-binding motif
TLR Toll-like receptor
TNFR Tumor necrosis factor receptor
TNF-α Tumor necrosis factor a
Trim 32 Tripartite motif-containing protein 32
TRPC1 Transient receptor potential channel 1
TWEAK TNF-related weak inducer of apoptosis
YAP Yes-associated protein
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